Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

Glicentin Rat ELISA

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antibody
  • Species:Rat
Please select your region to see available products and prices.
Cat. No. Size Price


RSCYK111R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Competitive ELISA, Immobilized antibody

Applications

Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

30 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.206–50 pmol/ml

Intra-assay (Within-Run)

CV = 4.56 - 7.82

Inter-assay (Run-to-Run)

CV = 3.16 - 7.59

Spiking Recovery

Rat plasma A - 95,72% Rat plasma B - 92,34%

Summary

Research topic

Animal studies

Summary

Glicentin is a 69-amino-acid peptide containing glucagon and oxyntomodulin sequences in the molecule. It is
suggested that glicentin and oxyntomodulin are produced in the intestinal L-cells and glucagon in A-cells
in the pancreas, these peptides are derived from a common precursor by two different tissue-specific processing
pathways. In 1983, the amino acid sequence of human glicentin was deduced by Bell et al. from the genomic
sequence of human preproglucagon. Glicentin is a major form of gut glucagon-like immunoreactants (Gut GLIs).
In mammalian small intestine, proglucagon is processed into glicentin, oxyntomodulin, and glucagon -like peptide
1(GLP-1) and glucagon -like peptide 2 (GLP-2). GLP-1(7-37) and GLP-1(7-36)amide have been isolated from
the intestine and pancreas. It has been known that the GLP-1 sequence is well conserved between species in all
mammals studied. Using synthetic peptides, several investigators have demonstrated that in contrast to GLP-1 (1-37), truncated GLP-1(7-36)amide and GLP-1(7-37) have several physiological effects. However, the physiological role of glicentin, a major gut glucagon, is still unclear. It has been known that the circulating level of plasma glicentin-like peptides increases significantly nutrient ingestion. Yanaihara institute Inc. has succeeded in developing a specific and convenient EIA kit for determination of rat glicentin in plasma.

References to Product

References

  • Ishihara, S. et al.: Helicobacter pylori infection accelerates gene expression of glicentin in gastric mucosa. Its association with intestinal metaplasia of the stomach. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 32: 460-464, 1997
  • Ohneda, A. et al.: Effect of glicentin-related peptides on glucagon secretion in anaesthetized dogs. DIABETOLOGIA 29: 397-401, 1986
  • Ohneda, A. et al.: Effect of intraluminal administration of amino acids upon plasma glicentin. DIABETES RESEARCH AND CLINICAL PRACTICE 5: 265-270, 1988
  • Ohneda, A. et al.: Insulinotropic action of human glicentin in dogs. METABOLISM, CLINICAL AND EXPERIMENTAL 44: 47-51, 1995
  • Shibata, C. et al.: Effect of glucagon, glicentin, glucagon-like peptide-1 and -2 on interdigestive gastroduodenal motility in dogs with a vagally denervated gastric pouch. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 36: 1049-1055, 2001
Related Products Documents